Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT06742853
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 2000
- Registration Number
- NCT06686615
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06450366
- Locations
- 🇮🇱
Yitzhak Shamir Medical Center. ( Site 0702), Beer Yaakov, Israel
🇮🇱Rambam Health Care Campus ( Site 0700), Haifa, Israel
🇮🇱Meir Medical Center. ( Site 0703), Kfar Saba, Israel
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 140
- Registration Number
- NCT06437574
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 204691
- Registration Number
- NCT05974345
- Locations
- 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
- Conditions
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT05763875
- Locations
- 🇺🇸
Southern Clin Research Clinic ., Zachary, Louisiana, United States
🇲🇽Novartis Investigative Site, Queretaro, Mexico
🇺🇸Hillcrest Medical Research, DeLand, Florida, United States
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Policlinico Casilino ASL RMB
- Target Recruit Count
- 50
- Registration Number
- NCT04659525
- Locations
- 🇮🇹
Policlinico Casilino, Rome, Italy
Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Orient Pharma Co., Ltd.
- Target Recruit Count
- 390
- Registration Number
- NCT04643093
- Locations
- 🇨🇳
E-Da Hospital, Kaohsiung, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Tri-Service General Hospital, Taipei, Taiwan
Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Policlinico Casilino ASL RMB
- Target Recruit Count
- 50
- Registration Number
- NCT04397653
- Locations
- 🇮🇹
Policlinico Casilino, Rome, Italy
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 10
- Registration Number
- NCT03933293
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.